Try our beta test site
Trial record 16 of 23 for:    eplerenone | Open Studies

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Herlev Hospital
Sponsor:
Information provided by (Responsible Party):
Marie Louise Johansen, Herlev Hospital
ClinicalTrials.gov Identifier:
NCT02809963
First received: June 16, 2016
Last updated: June 19, 2016
Last verified: June 2016
  Purpose
The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.

Condition Intervention Phase
Diabetes Type 2
Drug: Eplerenone
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study)

Resource links provided by NLM:


Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • Liver fat content [ Time Frame: 26 weeks ]
    changes in liver fat content by proton MR spectroscopy


Secondary Outcome Measures:
  • Fat mass distribution [ Time Frame: 26 weeks ]
    Changes in body fat distribution (total body fat, visceral fat, subcutaneous fat)

  • insulin resistance [ Time Frame: 26 weeks ]
    Changes in insulin resistance by HOMA and Matsuda index

  • Urinary albumin/creatinine ratio [ Time Frame: 26 weeks ]
    changes in Urinary albumin/creatinine ratio

  • Biomarkers of adipocyte function [ Time Frame: 26 weeks ]
    Changes in biomarkers of adipocyte function (adiponectin, leptin, FGF-21, TNF-alfa, FFA, IL-6, MCP-1, MAC-1)

  • 24 Hour blood pressure [ Time Frame: 26 weeks ]
    changes in 24 Hour blood pressure

  • Global longitudinal strain (GLS) [ Time Frame: 26 weeks ]
    changes in global longitudinal strain by echocardiography

  • systolic and diastolic function og left ventricule [ Time Frame: 26 weeks ]
    changes in systolic and diastolic function of left ventricule by echocardiography

  • Regional and global fibrosis by cardiac magnetic resonance [ Time Frame: 26 weeks ]
    changes in regional and global fibrosis using Late gadolineum enhancement cardiac magnetic resonance

  • biomarkers of myocardial stress and fibrosis [ Time Frame: 26 weeks ]
    changes in biomarkers of myocardial stress and fibrosis (NT-proBNP, MR-proANP, galectin-3, GDF-15, MR-proADM)

  • pulse wave analysis [ Time Frame: 26 weeks ]
    changes in pulse wave analysis

  • Quality of life [ Time Frame: 26 weeks ]
    changes in quality of life using WHO-5

  • Quality of life [ Time Frame: 26 weeks ]
    changes in quality of life using W-BQ12


Estimated Enrollment: 130
Study Start Date: November 2015
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eplerenone
Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
Drug: Eplerenone
50 mg tablets, oral use.
Placebo Comparator: placebo
sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
Drug: Placebo
50 mg tablets, oral use

Detailed Description:

In this randomized, double-blind, placebo-controlled study we want to investigate the effect of mineralocorticoid receptor antagonists in type 2 diabetes patients on myocardial function, glucose and fat metabolism.

Background The mortality rate in T2 DM is still increased by almost a factor 2 although poly pharmacological therapy of risk factors has been recommended for years. Treatment with MR antagonists in patients with primary hyperaldosteronism and systolic heart failure improves insulin resistance, myocardial function and prognosis. Further, recent evidence has suggested that aldosterone participates in the regulation of glucose and lipid metabolism, as MR expression has been identified in adipocytes and beneficial metabolic effects of selective MR blockade has been demonstrated in several animal models. Notably, there is no available data in humans with T2DM.

A key feature of T2 DM is altered body composition characterized by increased metabolic active visceral adipose tissue (VAT) and increased fat content of the liver, which has been associated with cardiac dysfunction and outcome. Gold standard for measurement of VAT is magnetic resonance imaging (MRI), and proton MRI spectroscopy can quantitatively measure fat content in the liver with high precision. The pathogenesis of myocardial dysfunction in T2DM is linked with insulin resistance (IR) of adipose tissue mediating increased supply of free fatty acids and intra myocardial lipid accumulation. Thus, beneficial effects of lipid metabolism could in theory indirectly improve myocardial function in type 2 diabetics.

Global longitudinal strain (GLS) is a validated method for evaluating regional and global function of the left ventricle, which is a strong predictor of incident HF in patients with myocardial infarction and closely related with plasma NT-proBNP concentrations.

Hypothesis Selective blocking of the MR receptor in patients with T2 DM improves insulin resistance, lipid metabolism and myocardial function.

Objectives To investigate the effect of Eplerenone 100-200 mg once daily compared to placebo in patients with type 2 diabetes with regard to glucose and lipid metabolism, myocardial function and structure, and vascular function.

The primary objective is to investigate the effect of Eplerenone 100-200 mg once daily compared to placebo on changes in liver fat content.

Design A single center, randomized, double blinded placebo controlled trial. Patients with T2 DM and high risk of cardiovascular disease will be randomized to either Eplerenone 100-200 mg or placebo daily for 26 weeks. Patients will be investigated at baseline and after 26 weeks.

A total of 130 patients with type 2 diabetes will be included.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to understand the written patient information and to give informed consent
  • Type 2 diabetes mellitus (WHO criteria), diagnosed at least 3 months prior to baseline
  • Blood pressure treatment according to standard guidelines
  • Negative pregnancy test (fertile women)
  • Be willing to change/pause potassium sparing medication
  • Age 18-85 years
  • Patients must have high cardiovascular risk factors, defined as one of the following:

NT-proBNP ≥ 70 pg/ml (taken within the last 6 months prior to baseline) Albuminuria ( albumin/creatinine ratio ≥ 30 mg/g Confirmed history of myocardial infarction (≥ 3 months prior to baseline) Or patient discharged from hospital with a documented diagnosis of unstable angina within 24 months prior to baseline Evidence of coronary artery disease by CAG in 1 or more major coronary arteries OR at least one of the following: a positive noninvasive stress test, OR a positive stress echocardiography showing regional systolic wall motion abnormalities, OR a positive scintigraphy test showing stress-induced ischemia History of ischemic or hemorrhagic stroke (≥ 3 months prior to informed consent) Presence of peripheral artery disease (symptomatic or not ) documented by either: previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency; or angiographic evidence of significant (≥ 50%) peripheral artery stenosis in at least one limb; or evidence from a non-invasive measurement of significant (≥50% or as reported as hemodynamically significant) peripheral artery stenosis in at least one limb; or ankle brachial index of ≤ 0.9

Left ventricle hypertrophy:

Documented at echocardiography ECG: R-spike in V5/V6 ≥ 25 mm or S-spike in V1 + R-spike in V5/V6 ≥ 35 mm Patients both with and without a cardiovascular risk factor can be randomized to the fat biopsy sub study.

Exclusion Criteria:

  • Allergic to the study medication
  • Systolic HF (LVEF ≤ 40%)
  • Impaired kidney function, eGFR ≤ 40 ml/min
  • Severe liver insufficiency (Child-Pugh class C)
  • Treatment with MR antagonist within 3 months prior to baseline
  • Treatment with both ACE inhibitors and Angiotensin II Receptor blockers.
  • Serum-potassium ≥ 5.0 mmol/l
  • Serum-sodium ≤ 135 mmol/l
  • Myocardial infarction, unstable angina pectoris or bypass graft surgery within 3 months prior to baseline
  • Persistant atrial fibrillation (except for the fat biopsy sub population)
  • ECG showing malign ventricular arrhythmia or prolonged QT-interval (> 500ms)
  • Untreated heart valve disease
  • ICD-unit/pacemaker
  • Pregnancy or desire hereof or breastfeeding
  • Women in the fertile age not using safe contraceptives (spiral, hormonal contraceptives)
  • Cancer unless complete remission ≥ 5 year
  • Alcohol-/drug-abuse
  • Inflammatory bowel disease
  • Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable to participate in the study
  • Simultaneous participation in another clinical study
  • Treatment with CYP3A4-inhibitors (e.g. itraconazol, etoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodon)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02809963

Contacts
Contact: Caroline Kistorp, MD, PhD, associate proffessor +4538689536 caroline.michaela.nervil.kistorp@regionh.dk
Contact: Marie Louise Johansen, MD, PhD student +4520726589 marie.louise.johansen.02@regionh.dk

Locations
Denmark
Herlev Hospital, department of internal medicine, endocrine research unit Recruiting
Herlev, Denmark, 2730
Contact: Caroline Kistorp, MD, PhD. associate professor    +4538689536    caroline.michaela.nervil.kistorp@regionh.dk   
Contact: Marie Louise Johansen, MD, Phd student    +4520726589    marie.louise.johansen.02@regionh.dk   
Sponsors and Collaborators
Herlev Hospital
  More Information

Responsible Party: Marie Louise Johansen, MD, PhD student, Herlev Hospital
ClinicalTrials.gov Identifier: NCT02809963     History of Changes
Other Study ID Numbers: 2015-002519-14 
Study First Received: June 16, 2016
Last Updated: June 19, 2016
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Eplerenone
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Mineralocorticoid Receptor Antagonists
Spironolactone
Mineralocorticoids
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents
Hormones

ClinicalTrials.gov processed this record on February 27, 2017